- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Gary Lyman, MD, MPH: Biosimilar G-CSFs and the Cost of Care
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilar granulocyte colony-stimulating factor (G-CSF) therapies have impacted cancer care.
Transcript
Again, we're very early. The first biosimilar [granulocyte colony-stimulating factor, G-CSF] was approved just in recent years. We now have another biosimilar that was approved as an originator, tbo-filgrastim, and 2 true biosimilars in the [United States], the forms of filgrastim, and now just over the last few months approval of the long-acting filgrastim, pegfilgrastim, which has been available in Europe but now is also available in the [United States].
But this is brand new data. In fact, in many institutions, it isn’t even available yet as the drug gets distributed. So the only data that we have is from the filgrastim originator versus the filgrastim-sndz, which was approved a couple of years ago, and the data there suggest there's been rapid uptake of the biosimilar filgrastim; at least half, maybe two-thirds of the utilization of G-CSF in the United States has switched from the original drug to the biosimilar.
The impact on cost is more challenging, and again very preliminary data. But as I alluded to, perhaps showing around a 10% the 12% decrease in price over the first year or 2 of the use of the biosimilars.
One will expect (again, in Europe, they’ve seen this) with time and with more and more competition, more and more biosimilars, there will be further reductions in pricing, perhaps to the extent of a 20% to 30% decrease.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
